Market Place
Sourcing Support
VYNE Therapeutics Q3 2024 Results & Business Update
07 Nov 2024 //
GLOBENEWSWIRE
VYNE Therapeutics Reports Positive Phase 1a SAD Data For VYN202
12 Sep 2024 //
GLOBENEWSWIRE
VYNE Therapeutics to Participate in September Investor Conferences
03 Sep 2024 //
GLOBENEWSWIRE
VYNE Therapeutics Reports Q2 2024 Financial Results And Business Update
14 Aug 2024 //
GLOBENEWSWIRE
VYNE Therapeutics Granted Patent For VYN202 BET Inhibitor
16 Jul 2024 //
GLOBENEWSWIRE
VYNE Therapeutics Appoints New SVP Of Clinical Development
09 Jul 2024 //
GLOBENEWSWIRE
VYNE Therapeutics to Participate in Leerink Partners Therapeutics Forum
26 Jun 2024 //
GLOBENEWSWIRE
VYNE Announces First Participants in Phase 1a Trial of Novel BD2-Selective
13 Jun 2024 //
GLOBENEWSWIRE
Advanced Medicine: $32M Financing, Two New Board Members
05 Jun 2024 //
GLOBENEWSWIRE
VYNE Reports First Quarter 2024 Financial Results and Provides Business Update
09 May 2024 //
GLOBENEWSWIRE
VYNE Therapeutics Announces US FDA clearsIND for VYN202
08 May 2024 //
PHARMABIZ
VYNE Gets FDA IND Clearance For BET Inhibitor VYN202
06 May 2024 //
GLOBENEWSWIRE
VYNE: VYN201 Oral Presentations At SID 2024 Annual Meeting
01 May 2024 //
GLOBENEWSWIRE
VYNE Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune
19 Mar 2024 //
GLOBENEWSWIRE
VYNE Reports 2023 Fourth Quarter and Year-End Financial Results
29 Feb 2024 //
GLOBENEWSWIRE
VYNE to Participate in the TD Cowen 44th Annual Health Care Conference
21 Feb 2024 //
GLOBENEWSWIRE
VYNE Announces Positive Biomarker Data from Successful Phase 1b Trial of VYN201
10 Jan 2024 //
GLOBENEWSWIRE
VYNE Therapeutics Appoints Christine Borowski, Ph.D., to its Board of Directors
03 Jan 2024 //
GLOBENEWSWIRE
VYNE Therapeutics Reports Third Quarter 2023 Financial Results
13 Nov 2023 //
GLOBENEWSWIRE
VYNE Therapeutics to Host Virtual R&D Day Event on November 9, 2023
07 Nov 2023 //
GLOBENEWSWIRE
VYNE Announces Closing of Previously Announced Private Placement of $88.2M
01 Nov 2023 //
GLOBENEWSWIRE
VYNE Therapeutics Announces Positive Data from Phase 1b Trial for VYN201
30 Oct 2023 //
GLOBENEWSWIRE
VYNE Therapeutics Announces Private Placement of $88 Million
30 Oct 2023 //
GLOBENEWSWIRE
VYNE Therapeutics Reports Positive Results from Preclinical Models for VYN202
30 Oct 2023 //
GLOBENEWSWIRE
Vyne aims to raise $88M; Sanofi invests in gene therapy company
30 Oct 2023 //
ENDPTS
VYNE to Participate in H.C. Wainwright 25th Annual Global Investment Conference
06 Sep 2023 //
GLOBENEWSWIRE
VYNE Therapeutics Reports Second Quarter 2023 Financial Results
14 Aug 2023 //
GLOBENEWSWIRE
VYNE Therapeutics to Attend BIO International Convention
18 May 2023 //
GLOBENEWSWIRE
VYNE Therapeutics Reports First Quarter 2023 Financial Results
11 May 2023 //
GLOBENEWSWIRE
VYNE Therapeutics Announces Selection of Development Candidate VYN202
01 May 2023 //
GLOBENEWSWIRE
VYNE Announces Positive Preclinical Data for Inhaled Formulation of VYN201
19 Apr 2023 //
GLOBENEWSWIRE
VYNE Therapeutics Announces Positive Data for Inhaled Formulation of VYN201
19 Apr 2023 //
PRESS RELEASE
VYNE Announces Positive First-In-Human Pharmacokinetic and Hematology Data
30 Mar 2023 //
GLOBENEWSWIRE
VYNE Therapeutics to Participate in H.C. Wainwright Autoimmune Conference
22 Mar 2023 //
GLOBENEWSWIRE
Vyne swings behind BET, seeks partner for failed eczema drug
10 Mar 2023 //
FIERCE BIOTECH
VYNE Reports Year-End 2022 Financial Results and Provides Business Update
09 Mar 2023 //
GLOBENEWSWIRE
VYNE Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Rule
28 Feb 2023 //
GLOBENEWSWIRE
VYNE Therapeutics to Participate in the 43rd Annual Cowen Health Care Conference
22 Feb 2023 //
GLOBENEWSWIRE
VYNE reports positive data from trial of BET inhibitor for vitiligo
16 Feb 2023 //
CLINICAL TRIALS ARENA
VYNE Therapeutics Announces Reverse Stock Split
10 Feb 2023 //
GLOBENEWSWIRE
VYNE Announces First Vitiligo Patient Dosed in Phase 1a/b Clinical Trial
09 Jan 2023 //
GLOBENEWSWIRE
VYNE Therapeutics to Participate in the LifeSci Partners 12th Access Event
12 Dec 2022 //
GLOBENEWSWIRE
VYNE Therapeutics Announces First Patent Granted for Novel BET Platform
07 Dec 2022 //
GLOBENEWSWIRE
VYNE Therapeutics to Participate in Cantor Fitzgerald’s Medical & Aesthetic
02 Dec 2022 //
GLOBENEWSWIRE
VYNE Announces First Subjects Dosed in Phase 1a/b Clinical Trial
17 Nov 2022 //
GLOBENEWSWIRE
VYNE Therapeutics Reports 3Q 2022 Financial Results and Provides Business Update
10 Nov 2022 //
GLOBENEWSWIRE
VYNE Therapeutics Announces Results from its Phase 2a Trial of FMX114
10 Aug 2022 //
GLOBENEWSWIRE
VYNE Tx to Present at the B&T Cell-Mediated ADDD Conference
19 Jul 2022 //
GLOBENEWSWIRE
VYNE concludes enrolment in Phase IIa atopic dermatitis therapy trial
20 Jun 2022 //
CLINICALTRIALSARENA
VYNE Tx Completes Enrollment in PIIa Trial of FMX114 for Atopic Dermatitis
17 Jun 2022 //
GLOBENEWSWIRE
VYNE Therapeutics to Present at LifeSci PII Symposium on May 10th
06 May 2022 //
GLOBENEWSWIRE
VYNE Tx Shows Positive Phase 1b Efficacy Data for FMX114 from Phase 1b/2a Trial
07 Apr 2022 //
GLOBENEWSWIRE
VYNE Reports Positive Preclinical Data for Intra-Articular Injection of VYN201
30 Mar 2022 //
GLOBENEWSWIRE
VYNE Tx Reports Year-End 2021 Financial Results
17 Mar 2022 //
GLOBENEWSWIRE
VYNE Reports Positive PC Data for Lead BET Inhibitor, VYN201
07 Mar 2022 //
GLOBENEWSWIRE
VYNE Therapeutics to Present at 42nd Annual Cowen Healthcare Conference
03 Mar 2022 //
GLOBENEWSWIRE
VYNE Therapeutics Shows Phase 1b Data for FMX114 from Phase 1b/2a Trial in AD
19 Jan 2022 //
GLOBENEWSWIRE
Journey Medical Acquires 2 FDA-Approved Topical Minocycline Products from VYNE
13 Jan 2022 //
GLOBENEWSWIRE
VYNE Therapeutics Enrolls First Patient in Clinical Trial of FMX114
19 Oct 2021 //
GLOBENEWSWIRE
VYNE THERAPEUTICS Management`s Discussion and Analysis of Financial Condition
11 Oct 2021 //
MARKETSCREENER
